Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05744401 · ClinicalTrials.gov registry record · Phase 2
A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease
A Phase 2 study, sponsored by Alector.
- Terminated
- Registry status
- Phase 2
- Development phase
- 197
- Enrollment target
NCT05744401 is a Phase 2 study that was terminated before completion, run by Alector. The registered enrollment target is 197 participants.
The verdict
NCT05744401, a Phase 2 study, was terminated before completion, sponsored by Alector.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 197 participants
- Enrollment target
Study Summary
A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
Interventions
- DRUG AL002
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 197 participants |
| Start Date | 2023-01-04 |
| Est. Completion | 2025-02-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05744401
The ClinicalTrials.gov registry entry for NCT05744401 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 197 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alector, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AL002 is the first listed.
NCT05744401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05744401 about?
NCT05744401 is a clinical study titled "A Long-term Extension Study to Evaluate Safety, Tolerability, and Efficacy of AL002 in Alzheimer's Disease". A long-term extension study to evaluate the safety, tolerability, and efficacy of AL002 in participants with Early Alzheimer's Disease.
What is the current status of trial NCT05744401?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 197 participants. The study started on 2023-01-04. Estimated completion is 2025-02-05.
What interventions are being tested in trial NCT05744401?
The interventions under investigation include: AL002 (DRUG).
Who is sponsoring clinical trial NCT05744401?
This trial is sponsored by Alector, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.